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The future of quality of life is in our hands 
Jaap C. Reijneveld – Newsletter Editor 
Neurologist, Department of Neurology, VU University Medical Center and Academic Medical Center, Amsterdam, The Netherlands
                                                                      
W    ith pride I present the 2016 issue of the annual Newsletter of the Quality of Life Group of the 
European Organisation for Research and 
Treatment of Cancer (EORTC) !
This Newsletter serves as a way to inform 
the members of the Group as well as people 
at further distance – varying from members 
of the other EORTC groups and the EORTC 
headquarters who are interested, but not 
actually involved, in the Group’s activities, 
to people who are just fascinated by the 
Group’s name. If you are a member, you don’t 
necessarily realise that we do in fact have 
a rather odd name. Several times I’ve had 
difficulties back home explaining to my family 
and friends that I would be abroad for a few 
days for the “Quality of Life Group”: a typical 
reply is “….must be hard-working, ha-ha…”
But in fact most Quality of Life Group (QLG) 
members do work hard, as is once again 
illustrated by the content of this Newsletter. 
The reader will be updated on the strategic 
projects of the QLG, such as the Computerized 
Adaptive Testing (CAT) and Computer-based 
Health Evaluation Software (CHES) projects, with 
impressive numbers of subjects being included 
and an equally impressive amount of work being 
done. Combining the strengths of the now-
completed CAT and CHES systems will hopefully 
bring Quality of Life (QoL) assessment within and 
outside of clinical trials to an even higher level. 
We also have reports of new research projects 
that are being funded by the QLG, involving the 
disease-oriented EORTC groups (DOGs) more 
and more, and leading to even more work to 
be done. Also in this issue is a very motivating 
contribution by a patient advocate, further 
emphasizing why we need to work hard.
Quality of Life Group members do enjoy 
relaxing after their hard work, though, and 
relaxing has happened and will happen 
throughout Europe, including Krakow and 
Manchester, as can be seen in the reports – 
and many pictures – on the most recent and 
upcoming QLG meetings.
I would like to thank Cheryl Whittaker for her 
indispensable help in creating this Newsletter, 
and very much hope that you will enjoy reading 
it, and looking to the future with QoL in mind.
issue n°16
EORTC QoL Group Meeting, Krakow, autumn 2015
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Travel new roads 
Lonneke van de Poll, Netherlands Cancer Institute, The Netherlands
T he times they are a-changin’ (1). As new chair of the Quality of Life Group (QLG) – although already halfway 
through my term – I sometimes find myself 
thinking that I became chair in a period 
with more changes in the EORTC landscape 
than ever. But talking with past chairs 
suggests that this has always been the 
same: nothing’s new. Flexibility to change 
is obviously needed to move with the times. 
Or, preferably, remain ahead of our time. 
In past years the QLG has anticipated that some 
of our old (paper) roads are rapidly ageing (1) 
and we have started to explore new ones. 
Important examples are the evolution of a 
Computerized Adaptive Testing (CAT) version 
of the EORTC QLQ-C30 and development of the 
Computer-based Health Evaluation Software 
(CHES). The latter facilitates the use of CAT 
measures, but also the integration of our core 
questionnaire in daily clinical practice. Another 
new road off the beaten module track is the 
development of a utility measure for the QLQ-
C30 (the QLU-C10D; see p.16), a collaboration 
led by QLG member and Prof. Madeleine King 
from the University of Sydney, Australia.
Also, following our ambition to really 
encourage collaboration between the QLG 
and Disease-Oriented Groups (DOGs), we have 
specifically invited DOG members to apply 
for funding for QoL projects as joint principal 
investigators with QLG members. Although 
2015 was the first grant round to have this 
new focus, we had interesting clinical projects 
submitted and were able to fund several 
projects that are joint with various DOGs. In 
this newsletter you can read more about these 
new joint clinical research projects. For 2016 
we expect more collaborative clinical research 
projects, and this will support the recently 
held EORTC strategy meeting outcome: to act 
as an integrated organization. 
Speaking of new roads, in a very recent 
paper in Clinical Cancer Research (2), the FDA 
states that there is a need to re-examine the 
measurement tools available to assess key 
health-related contributors to patients’ quality 
of life (QoL) in oncology clinical trials. Current 
use of static multi-item health-related quality 
of life (HRQoL) instruments is discussed in 
the paper and the FDA proposes a patient-
reported outcome assessment strategy 
that focuses on three separate measures of 
symptomatic adverse events, physical function 
and disease-related symptoms for use in 
clinical trials (2). The FDA also acknowledges 
that while they think these three core 
concepts may provide data more applicable 
to US regulatory requirements, collaboration 
among international stakeholders is needed 
to balance the needs of all parties. This new 
proposal for PRO assessment in oncology 
clinical trials will probably evoke a lot of 
discussion, but also requires research 
to evaluate whether this new approach 
may indeed be better than current use of 
multi-item HRQoL instruments. This year, the 
EORTC Quality of Life Group and Department 
will be well represented in this discussion by 
Mogens Grønvold and Andrew Bottomley 
at an annual Patient-Reported Outcomes 
Workshop with the FDA and international 
stakeholders from different backgrounds.
The times they are a-changin’ (1) – with new 
measures, new ways of assessment, and new 
strategies. But with our new collaborations and 
new friends it will be exciting to travel these 
new roads together.
References 
1.  The Times They Are a-Changin’, Bob Dylan 1964
2. Kluetz PG, Slagle A, Papadopoulos E, et al. Focusing 
on Core Patient-Reported Outcomes in Cancer Clinical 
Trials: Symptomatic Adverse Events, Physical Function, 
and Disease-Related Symptoms. Clin Cancer Res. 2016; 
Published OnlineFirst January 12, 2016; doi:10.1158/1078-
0432.CCR-15-2035 
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EORTC Quality of Life Group – facts & figures 
Irma Verdonck de Leeuw, VUMC Amsterdam, The Netherlands
A t   this moment we have 316 members (204 corresponding, 112 active and 10 from the department) all over the world, as you can see below. A total of 99 members of the EORTC QLG were present at the spring meeting at the EORTC EGAM 2015 in Brussels, Belgium and 88 at the autumn meeting in Krakow, Poland.
 
HOW CAN I  BECOME A FULL ACTIVE MEMBER ?
To become a full active member of the EORTC Quality of 
Life Group, you must attend two meetings (within two 
years) and be actively involved in research in the Group. 
 
On the third meeting you become an active member.
To maintain active membership you have to continue with 
research activities and attend two meetings every two years. 
 
If you are not able to attend meetings regularly, you can 
become a corresponding member.
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Anne-Sophie Darlington, QLG Executive Committee Web Representative, 
University of Southampton, UK  
Mélodie Cherton, Executive Assistant & Web Administrator, Quality of Life Department, 
EORTC Headquarters, Brussels, Belgium
Welcome 
to the intranet: 
the members’ area of the QLG website
We would like to report on progress that is being made in relation to the processes within the Quality of 
Life Group (QLG), as well as our aim to make 
our outputs and achievements more visible.
Firstly though, we would like to highlight 
that the secure active members’ area on the 
website ( http://groups.eortc.be/qol/welcome )
is successfully being used to register members 
for the upcoming meetings. 
One aspect within the active members’ area 
that we are currently focusing on in terms of 
development is the different life cycles. While 
we have clear guidelines for all the work that 
needs to be undertaken to develop modules 
and undertake projects on behalf of the 
QLG, some of the processes before and after 
the research work could benefit from being 
made more explicit. To this end, we have 
been working with the Module Development 
Committee (MDC) on developing visual 
representations of the different steps that 
researchers, the Executive Committee (EC), and 
other committees involved undertake from the 
inception of a good research question, through 
carrying out the research, to publishing the 
final papers. This is especially important as the 
Group is making great strides to work together 
with the EORTC clinical groups to answer 
clinically relevant and important questions, in 
addition to the prolific work on measurement 
development. This has diversified our research 
portfolio as well as increased the processes 
in complexity.
Another important aspect, in addition to 
developing improvements regarding the 
QLG’s members’ area, is to closely monitor 
research outputs from members of the QLG, 
as well as publicizing them. Publicizing the 
outputs will enable them to reach the widest 
possible audience and, through use of the 
questionnaires in trials and clinical practice, 
improve outcomes for cancer patients. The 
QLG not only publishes on the development 
of the outcome measures but also on our 
understanding of what is important in terms 
of quality of life (QoL) in a broader sense and 
on overviews of what we already know about 
cancer in relation to QoL and measurement for 
subgroups of patients. The development of a 
comprehensive publication strategy of the QLG 
will make sure that we collate all papers and 
abstracts published and disseminate this work 
as widely as we can through our website. 
Finally, we are always working on 
improvements and any feedback is always 
very much welcomed.
                                                                      
•  In September 2015 Kim Cocks moved 
to Adelphi Values as a Director and Principal 
Statistician in their Patient-Centered Outcomes 
team. The team provides expert consultancy 
and analysis in the field of patient-reported 
outcomes. Kim also retains a visiting contract 
with the University of York, UK.
•  Jaap Reijneveld was appointed 
Secretary of the Brain Tumor Group as of 
autumn 2015.
•  In 2015 Prof. Mogens Grønvold was 
appointed as an EORTC Board member – the 
first QLG Board member in 18 years to make 
the switch, so we congratulate Mogens and 
wish him the best of luck. 
                                                                      
Members’ news
IF, AS A QLG MEMBER, 
YOU HAVE SOME NEWS TO SHARE 
WITH THE QLG, 
WE WANT TO HEAR FROM YOU! 
SEND AN EMAIL TO CHERYL: 
cheryl.whittaker@eortc.be
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Andrew Bottomley, Assistant Director, EORTC, and Head of Quality of Life Departments, 
Brussels, Belgium
News from the 
EORTC Quality of Life Department
I t’s been another busy year at the Quality of Life Department (QLD). We have worked hard to keep on integrating 
the Department into the ever-changing 
organization, which, in turn, is having to 
adapt to the constantly moving and fast-
paced clinical trials area. Now that there 
are more regulations and oversight for the 
clinical trials that we carry out, it takes all 
hands to keep up. So, what are we doing? 
Well, we have lots to report.
We are preparing the ground for the 2017 
Quality of Life and Cancer Clinical Trials 
Conference, which will take place one year 
from now, in spring 2017. Once again, we 
are lucky that the European Parliament in 
Brussels has agreed to host us, with Member 
of the European Parliament (MEP) Marisa 
Matias once again helping us. This MEP from 
Portugal is proving to be a huge supporter of 
Quality of Life (QoL) and Cancer Clinical Trials 
in the EORTC. So with that support, as well as 
financial support from the EORTC Quality of 
Life Group (QLG) and other sponsors, we are 
well on track to having an exciting programme 
with many worldwide and QLG speakers. 
Please check the QLG website for the final date 
and programme, which will be announced 
soon. Besides conference planning, we have 
been active with lots of clinical trials. The 
EORTC has performed over 150 clinical trials 
with QoL since the Department was set up, 
and in 2015 some 17 were activated and 10 
involved QoL.  
The QLD is also working with the QLG on 
research projects, and in December 2015 
started a 3-year project on Minimal Important 
Differences (MID) to look at the clinical 
significance of QoL tools. In January this 
year, we started a project called SISAQOL 
(Standardizing International Statistical 
Analysis of QoL) which aims to make 
international guidelines for analysis of QoL 
data in randomized controlled trials (RCTs). 
We are pleased to say we now have over 30 
organizations on board, including FDA, EMA, 
HTA agencies, MASCC, ISPOR, ISOQOL, and 
CONSORT PRO. Our kick-off meeting at the 
end of January was the gathering of the 
great and the good, with presidents and past 
presidents of many cancer and international 
organizations present. But why do we need 
such key movers and shakers? Well, we have 
a challenge to face, as standardization of QoL 
is something that has not been achieved 
in the lifetime of RCTs – so if we are to do 
this, it’s the leaders who will help us. With 
a nice unrestricted educational grant from 
Boehringer Ingelheim, support from the EORTC 
HQ, and input from the QLG, we hope by 2019 
to be able to recommend these guidelines.
Since September 2015, we have been working 
hard on the new Item Bank (see p.8), with 
Dagmara Kuliś leading this project. It was 
important to first define the structure of the 
previous Item Bank and then work closely 
with the IT company on the development of 
the new one. Now the Translation Unit (TU) 
is busy populating the Item Bank, first with 
English items and then with all the translations, 
which – taking into account the large number 
of translated questionnaires – will take some 
time. The Item Bank can be accessed online 
(www.eortc.be/itembank/).
In general, it has been a busy year for the 
TU, with a higher-than-ever number of 
academic and commercial translations, 
and also translations used in Phase III and 
IV studies. Besides the Item Bank, the TU is 
also involved in other projects, such as the 
creation of ePRO guidelines, the update of the 
Translation Manual, and methodological work 
presented at the ISOQOL Annual Meeting and 
in publications.
The QLD is working closely with the EORTC 
Accounting and Contracting Departments, 
as contracting becomes more complex and 
the number of companies requiring license 
agreements increases year on year. Cheryl 
Whittaker, who is managing this liaison, also 
set up and launched an online user survey 
in September to see if we are meeting the 
needs of our clients. We are happy to report 
that the overwhelming response was that 
pharmaceutical companies are very happy 
with our provision of QoL tools for their clinical 
trials, as well as the information we provide, 
the speed of our support, and the license 
fees. The number of agreements signed with 
pharmaceutical companies certainly seems to 
reflect this: signed agreements increased from 
144 in 2014 to 168 in 2015, and the numbers 
look set to rise again this year. High numbers 
can also be seen in the academic download 
requests, handled by Mélodie Cherton: from 
March 2015 to the time of writing, there have 
been over 4,500 such requests.
Francesca Martinelli is actively coordinating 
the updating of the modules, and this work 
becomes more complex as more modules are 
developed and more grants are funded.
We’ve had a lot of new staff and fellows join 
the QLD in the last year: we now number 13. 
Back in July 2015 Edīte Fiskoviča was replaced 
by Tamara Sanchez as new Junior Translation 
Officer. In October 2015, Dr Jammbe Musoro 
joined the QLD as a biostatistician, and 
will be working on the MID project for the 
next three years. We have been lucky to 
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News from the 
EORTC Quality of Life Department
welcome a visiting researcher from France, 
Dr Jean-François Hamel, who is a rare breed: 
a medical doctor turned statistician. Initially 
he joined us to gain a little experience for a 
year, working on a simple analysis project, 
and has ended up doing brilliant work on no 
less than six projects… never come to the 
EORTC expecting life to be quiet! Finally, at the 
beginning of 2016, Dr Madeleine Pe joined 
the QLD to work on SISAQOL, which is already 
exploding, and other grant applications: again, 
it’s going to be a busy year ahead! Sadly, you 
can’t have gain without some loss – there is 
a rumour that Sheila Sanderson will retire this 
year after almost 20 years with us.
Many of the QLD staff travelled to 
conferences last year; we worked with the 
European Commission’s Joint Research Centre, 
looking at collaborating on Breast Cancer, and 
staff were invited to present at Head and Neck 
Conferences and other international meetings 
such as ASCO and ISOQOL. We also published 
a nice bunch of papers last year, many of 
which were in good impact factor journals 
addressing problems of methodology and 
statistical issues. You can keep updated on the 
website. 
Over the past year the QLD has carried out a 
lot of work preparing and supporting QLG 
initiatives. One of these was the Clinical 
Project Development Committee (CDC), which 
met in Krakow and then in London, and whose 
aim is to better integrate our activities with 
the 21 EORTC disease-oriented groups (DOGs). 
Another large part of the Department’s work 
has been the change in the grant review 
process, where the EORTC HQ and Board are 
now more active in reviewing and selecting 
grants, thereby supporting the QLG more, 
with the hope that we integrate more and 
enable the EORTC Board to be more in tune 
with QLG activities. Of course, coordinating 
this process means more work, but we worked 
well with the QLG Executive Committee (EC), 
the Grant Review Committee (GRC), and 
Board, and I think overall the process went 
well. Although it took a lot of effort, and a lot 
of the Department’s and HQ staff’s time, I think 
the end result was worth it. Success rates for 
grant applications are high, with over 70% of 
the submitted grants being funded. That’s 
impressive. Most of these grants get a lot of 
input and peer-review recommendations 
along the way, but final results are excellent. I 
am sure throughout 2016 we will continue to 
evolve and refine this process.
In addition, the new EORTC Quality Assurance 
policy required time as we standardized 
documents and procedures. As a consequence 
of the HQ changes we have had to attend 
several training sessions throughout the year, 
including the training of new QLD staff.
Further time and effort is anticipated for the 
increasing number of very specific incoming 
queries, especially from pharmaceutical 
companies using our questionnaires who 
expect a higher degree of service than 
academic users. As the original developers 
of the older modules retire and PIs move on, 
the QLD is losing that line of support and so 
must step up to the challenge of responding 
adequately to these queries. Additionally, a 
review of some of these older modules will 
be needed soon to systematically assess 
their impact and relevance. We also foresee 
an increase in queries related to ongoing 
developments in the EORTC QLQ projects: CAT 
is likely to generate questions of a technical, 
scientific, and administrative nature, while 
the QLU-C10D will open the field of health 
economics and health technology evaluations 
to the QLG, an area for which the QLG can only 
currently boast a few experts and the HQ only 
limited expertise. Finally, an increase in ePRO 
adaptations of the QLQ questionnaires by 
external vendors is also leading to an additional 
workload as advice and approval is sought by 
users for validation of their migrated versions.
So as you can see, it has been a busy year… 
and it’s going to get even busier!
LEFT TO RIGHT : Jean-François Hamel, Jammbe Musoro, Tamara Sanchez, Irina Ghislain, Sheila Scott Sanderson, Corneel Coens, Andrew Bottomley, 
Madeline Pe, Mélodie Cherton, Francesca Martinelli, Dagmara Kuliś, Cheryl Whittaker, Efstathios Zikos
quality of life group newsletter
SPRING 2016   7                                                                       
NEWSNEWS
 
New item bank 
                                                                      
The Item Bank is one of the flagship projects of the Quality of Life Group (QLG), providing an invaluable 
reference tool to both members of the QLG 
and external users. Naturally, to optimize 
searching for re-usable items, the platform 
has to be well searchable, but unfortunately 
in the previous version the search engine was 
not optimal. This and other problems (input 
and display of translations, linking identical 
and similar wordings, bugs) together with 
the fact that the previous version dates from 
2009 – which is another era when it comes 
to IT technologies – convinced the Executive 
Committee to approve the plan to develop 
a new version of the Item Bank.
After internal discussion at the meeting in 
Cyprus, we found an IT developer and in 
September last year we held two workshops 
with them to explain our needs and 
expectations. After a thorough functionality 
and usability analysis, the actual development 
began in January 2016 with nine weekly stages, 
each including a new release of the application, 
discussion on what was done and what 
should still be done, and testing. The EORTC 
HQ IT Department provided oversight of the 
integration process to ensure compatibility.
We are happy to report that the new Item 
Bank is now online and freely available to all 
QLG members and external users. It offers 
more searching options, better display of 
translations and wordings, more information on 
questionnaires and items, and a more modern 
and user-friendly design (see Figures 1 & 2 ).
We hope that the new Item Bank will serve you 
well and help in the process of developing new 
questionnaires.
Fig.1
Fig.2
Dagmara Kuliś, Quality of Life Department Translation Team Leader, 
EORTC Headquarters, Brussels, Belgium 
On behalf of the QLG Translation Committee (Eva Greimel, Graz, Austria & Michael Köller, Regensburg, Germany)
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New item bank 
Predicting 
the future by creating it 
Kathy Oliver, International Brain Tumour Alliance (IBTA)
                                                                      
The IBTA is a not-for-profit, limited liability company incorporated 
in England and Wales, Company Number: 6031485. Registered 
address: c/o Roxburghe House, 273-287 Regent Street, London 
W1B 2AD, UK. Address for correspondence: Kathy Oliver, Chair, 
IBTA, PO Box 244, Tadworth, Surrey, KT20 5WQ, United Kingdom. 
www.theitba.org
Many people, from US president Abraham Lincoln to educator and author Peter Drucker, have been 
credited with the words: “The best way to 
predict the future is to create it”. 
Regardless of this dictum’s origins, it should bring 
comfort and hope to those whose lives have been 
touched by cancer. It highlights the fact that we 
have some degree of control over what the future 
holds – if we get things right in the present.
Cancer research, treatment and support today 
bear witness to many promising advances, for 
example: innovative trial designs; unprecedented 
technological improvements; greater 
understanding of malignant disease mechanisms; 
and, importantly, a much stronger focus on quality 
of life (QoL) and how to measure it. 
One of the biggest revolutions and important 
advances in healthcare today is the increasing 
involvement of patients and caregivers. They 
are participating in defining priorities for cancer 
research; in helping shape clinical trials; in setting 
the agenda for their own care; and, at government 
level, in turning up the heat on medical issues 
relevant to their disease. No longer passengers 
but co-pilots, no longer subjects of research but 
partners in it, no longer passive recipients of care 
but active team members, patients and caregivers 
are front and centre.
Patient participation has become a vigorous 
movement. Writer and one-time neuroscience 
researcher Leonard Kish said: “If patient 
engagement were a drug, it would be the 
blockbuster drug of the century and malpractice 
not to use it”.
All very hopeful for a better future.
In the world of brain tumours (the community in 
which I am involved as a patient advocate), QoL 
is enormously important. Highly complex and 
multi-dimensional, QoL encompasses things like 
happiness, achievement, aspiration and many 
other aspects of a psychological, physical and 
sociological state of being. 
A malignant brain tumour – one of the most 
rapidly lethal of all cancers – attacks the very 
core of who a person is, resulting in devastating 
neurological and cognitive deficits. Quality 
of life for a brain tumour patient can be very 
badly affected across the whole spectrum of an 
individual’s physical and mental abilities. 
In such a setting, meaningful prolongation of 
life, with as good a quality of life as possible, 
is paramount.
What is meaningful – what constitutes quality of 
life for a brain tumour patient – is today assessed 
by various QoL tools. Numerous measures are 
available for use in clinical trials as well as in daily 
clinical work, although in practice QoL measures 
are not widely used in the latter context.
There are, however, criticisms of current QoL tools: 
that they are too ambiguous, not really indicative 
of the values and emotions of patients, often 
contradictory and inconclusive in their results, and 
lack consistency. 
Do current QoL tools adequately capture the state 
of a patient’s quality of life? And, crucially, does 
assessing QoL by using these tools result in any 
meaningful difference for patients? 
These questions need urgent review so that in the 
future we can provide medical professionals with 
correct assessments of what is truly perceived 
by patients and caregivers as a good – or at least, 
acceptable – quality of life. 
In mapping the future of QoL research over the 
next decade or so, I believe we should achieve 
the following:
1. Create guidelines on the most appropriate 
use of and format for QoL assessment tools (taking 
into account key cultural and societal differences) 
– and meaningfully involve patients and caregivers.
2. Establish international QoL expert networks 
so that data and knowledge-sharing can occur – 
and meaningfully involve patients and caregivers.
3. Implement training opportunities on QoL 
issues/assessment tools for healthcare 
professionals, industry representatives, academia, 
regulatory bodies – and meaningfully involve 
patients and caregivers.
4. Raise awareness in the general public (we 
are all potential patients) about what quality of 
life is and the importance of measuring it – and 
meaningfully involve patients and caregivers.
5. Develop new tools for QoL assessments 
which are based on evolving digital technology – 
and involve patients and caregivers.
Above all, we need to keep listening and talking 
to each other – now and in the coming decades 
– about quality of life for cancer patients and those 
who are important to them.
As cosmologist Stephen Hawking said: “Mankind’s 
greatest achievements have come about by 
talking, and its greatest failures by not talking…Our 
greatest hopes could become reality in the future…
All we need to do is make sure we keep talking.”
And, I would add once more, keep patients and 
caregivers at the heart of all aspects of quality of 
life assessment.
Dagmara Kuliś, Quality of Life Department Translation Team Leader, 
EORTC Headquarters, Brussels, Belgium 
On behalf of the QLG Translation Committee (Eva Greimel, Graz, Austria & Michael Köller, Regensburg, Germany)
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The added value of health-related 
quality of life assessment (CODAGLIO)
Combining clinical 
trial datasets 
in glioma patients:
                                                                       
Linda Dirven, Leiden University Medical Center, Department of Neurology, Leiden, The Netherlands
Jaap C. Reijneveld, VU University Medical Center, Department of Neurology, Amsterdam, The Netherlands 
Martin J.B. Taphoorn, Academic Medical Center, Department of Neurology, Amsterdam, The Netherlands; 
Medical Center Haaglanden, Department of Neurology, The Hague, The Netherlands
On behalf of the co-investigators : Neil Aaronson, Brigitta Baumert, Martin J. van den Bent, Andrew Bottomley, 
Corneel Coens, Francesca Martinelli, Roger Stupp, Andrea Talacchi, Wolfgang Wick and Efstathios Zikos
 
BACKGROUND
The incidence of primary brain tumours is 
low compared with other cancers such as lung 
and breast cancer, with primary brain tumours 
constituting only 2% of all adult cancers. 
Although the yearly incidence of gliomas is 
low, they do result in a disproportionate share 
of cancer morbidity and mortality. Patients 
with a glioma differ from the general cancer 
population in that they not only have cancer, 
but also suffer from a progressive brain disease. 
Glioma patients demonstrate a high symptom 
burden, and disease-specific symptoms such as 
cognitive dysfunction, seizures and progressive 
neurological deficits prevail. Although patients 
receive multi-modal treatment with surgery, 
radiotherapy and chemotherapy, current 
treatment options are not curative. Therefore, 
the quality of survival, typically assessed 
with measures of health-related quality of 
life (HRQoL), is for these patients at least as 
important as the duration of survival. 
WHICH CLINICALLY RELEVANT QUESTIONS DO 
WE WANT TO ANSWER ? 
1. Is HRQoL a prognostic indicator of 
(progression-free) survival ?
To improve survival prediction for individual 
glioma patients, data on baseline HRQoL may 
be used in conjunction with established 
prognostic factors such as age, performance 
status and tumour grade. Although there are 
indications that HRQoL is prognostic of overall 
survival, these results are based on small sample 
sizes. We therefore aim to assess in a large 
dataset which baseline HRQoL items/scales of 
the QLQ-C30 and QLQ-BN20 questionnaires are 
independently associated with progression-free 
and overall survival. 
2. Can HRQoL be a stratification factor in 
future (EORTC) brain trials?
If HRQoL appears to be an important prognostic 
factor for survival, it may be considered as a 
stratification factor for future clinical trials. In 
that case, proper HRQoL scales need to be 
selected and cut-offs need to be determined. 
This stratification would ensure that treatment 
groups are comparable on those specific HRQoL 
factors, enhancing conclusions drawn on 
treatment efficacy. 
3. Are specific symptom clusters associated 
with a deterioration in HRQoL?
A symptom cluster is a group of two or more 
symptoms that occur simultaneously, are 
interrelated and may or may not have a 
common aetiology. Compared to a single 
symptom, simultaneously occurring symptoms 
may have a more detrimental effect on HRQoL. 
Identification of symptom clusters that are 
associated with a deterioration in HRQoL 
(overall HRQoL and functioning scales) is 
essential for direct management of the disease, 
which may subsequently result in improved 
HRQoL. 
4. Is HRQoL maintained/improved during 
progression-free survival time?
Many studies performed in glioma patients 
found that new treatments did not improve 
overall survival, but did prolong progression-
free survival. For patients it is important that 
HRQoL during their progression-free time will 
be maintained or improved. By evaluating 
HRQoL during progression-free survival time, 
we will be able to determine the impact of a 
specific treatment regimen on HRQoL.  
5 . Will a combined analysis of survival and 
HRQoL data facilitate interpretation on the 
net clinical benefit of a treatment strategy ? 
Currently, data on survival and HRQoL are 
independently analyzed. Nevertheless, 
interpretation of the net clinical benefit of a 
treatment strategy, which may subsequently 
impact clinical decision-making, may be 
facilitated by combining survival and HRQoL 
data into one outcome. Two statistical methods 
combining measures of quantity and quality 
of survival will be applied to determine the 
net clinical benefit of different trials. This will 
allow comparability across glioma trials and 
may guide towards the best treatment for 
these patients.
HOW ARE WE GOING TO ANSWER THESE 
QUESTIONS ?
We will combine clinical and HRQoL data 
of all available closed RCTs including glioma 
patients. We will have access to RCTs conducted 
by (members of ) the EORTC Brain Tumour 
Group, with at least 3,917 glioma patients with 
baseline HRQoL. This number may increase to 
almost 6,000 patients if we are able to include 
RCTs which were conducted by other research 
groups.
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Development 
of the EORTC 
questionnaire 
for individuals at risk of Hereditary Cancer 
Predisposition Syndrome: the EORTC QLQ-HCPS
Anne Oberguggenberger & Monika Sztankay, Department of Psychiatry, Psychotherapy 
and Psychosomatics, Medical University of Innsbruck, Austria 
Vassilios Vassiliou, Bank of Cyprus Oncology Centre, Nicosia, Cyprus 
                                                                      
T he identification of hereditary genetic variations associated with increased cancer risk – so-called 
Hereditary Cancer Predisposition Syndromes 
(HCPS) – has become an integral part of 
routine oncology practice (1).  
Familial or hereditary cancer, such as Lynch 
Syndrome or hereditary breast and ovarian 
cancer (BRCA1/BRCA2), can affect individuals 
in a number of ways, impacting on their quality 
of life (QoL). Individuals at risk of inheriting 
predisposing genetic variants may be offered 
genetic testing, which can provide prognostic 
information on individual cancer life-time risk 
and risk for cancer recurrence (2, 3). This entails 
anxiety, cancer worry or feelings of guilt and 
concern for other family members also eligible 
for testing. Additionally, individuals with a 
known HCPS (e.g. inheritors of autosomal 
dominant or sex-linked mutations) are advised 
to have regular screening examinations 
or definitive prophylactic treatments (e.g. 
prophylactic removal of susceptible organs) 
aimed at the reduction of the risk of developing 
cancer or diagnosing a new cancer at an 
early stage. Associated QoL issues relate to 
potential physical impairments, worries or 
cosmetic problems.
Genetic testing is employed in comprehensive 
genetic counselling (GC) programmes, 
including psychosocial consultation. Even 
though available scientific evidence has not 
illustrated that GC is associated with overall 
serious psychological morbidity in the long 
term, a quarter of counsellees experience 
clinically relevant psychological adverse 
effects as well as QoL impairments regardless 
of the test result (4). In addition, about 25% of 
counsellees report unmet psychological care 
needs (5).
Moreover, the group of mutation carriers 
not affected by cancer but advised to 
undergo prophylactic procedures is still 
underrepresented in clinical research. The 
long-term effect on QoL in this group needs 
to be systematically studied in future trials 
(e.g. long-term impact of preventive strategies 
such as surveillance or cancer worry). Based 
on the above, future research activities need 
to engage in systematically studying the long-
term effects on QoL in these “new” patient 
groups. QoL research should focus not only on 
QoL demands of cancer patients confronted 
with HCPS but also on their relatives who 
might, although healthy, be at an increased life-
time risk of developing cancer (in the case of a 
diagnosed HCPS). 
The EORTC Quality of Life Group (QLG) has 
kindly decided to fund the development 
of an HCPS core questionnaire. This 
questionnaire will be used to systematically 
determine short- and long-term QoL issues 
and concerns in cancer patients and healthy 
individuals with or at risk of HCPS in order 
to provide the best medical care. Moreover, 
the EORTC QLQ-HCPS can be applied for the 
systematic evaluation of HCPS counselling 
programmes and related impairments 
of QoL with the intention of improving 
the effectiveness and efficacy of genetic 
counselling. Our working group has already 
done preliminary work on the structural 
concept and we are ready to start the project. 
After Phase I and analysis of results it will be 
decided if additional modules on specific 
HCPS will need to be developed in addition 
to the core HCPS questionnaire.
References 
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Study on European norm data 
for the EORTC CAT is about to start 
 
Sandra Nolte, Department of Psychosomatic Medicine, Center for Internal Medicine 
and Dermatology, Charité - Universitätsmedizin Berlin, Germany
 
                                                                      
On behalf of the co-investigators : Neil Aaronson, Anna Costantini, Peter Fayers, Mogens Grønvold, 
Bernhard Holzner, Colin Johnson, Georg Kemmler, Morten Aagaard Petersen, Matthias Rose, Krzysztof Tomaszewski, 
Annika Waldmann & Teresa Young
 
The EORTC Quality of Life Group (QLG) is in its final stages of developing and launching a computerized adaptive 
testing (CAT) version of the QLQ-C30. The main 
idea behind CAT is that it administers more 
relevant and informative items by tailoring 
the instrument to the individual respondent. 
The development of the EORTC CAT includes 
several members of the QLG and is headed 
by Mogens Grønvold and Morten Aagaard 
Petersen (see p.14). 
The EORTC CAT project is an enormous effort 
of developing and validating 14 item banks 
representing the 14 symptoms and functions of 
the QLQ-C30. To date, all item banks have been 
finalized, including translations into Chinese, 
Danish, Dutch, German, Italian, Polish and Turkish, 
and partial translations into French, Spanish 
and Swedish. Further, the feasibility study of 
the EORTC CAT has just been completed, with 
preliminary results suggesting great acceptance 
and feasibility of the instrument. Following 
on from these results, as Mogens and Morten 
mention in their article in this newsletter, the 
field study including n=1,000 cancer patients 
from several countries is about to start.
To make a CAT fully functional, however, it is 
not quite sufficient to undertake a thorough 
validation of the instrument and calculate 
individual item parameters as part of Item-
Response Theory (IRT). This circumstance is 
due to the nature of the scores (theta) that a 
CAT produces. That is, theta scores on their 
own do not have a direct meaning as they are 
placed on an “arbitrary” metric, hampering 
score interpretation. A meaningful and sensible 
interpretation can only be achieved by linking 
the CAT to a reference population, which 
may be obtained from clinical or general 
population samples.
We are pleased to announce that this final 
crucial step of the EORTC CAT project has 
just been launched. We received two years 
of funding to undertake a large European 
study to obtain such norm data. The reference 
population will include about 12 European 
countries that will be carefully selected 
based on size of the country (the number of 
people speaking the respective language), 
geographical location (an even spread between 
north, east, south, and west), and the respective 
country’s EORTC QLQ-C30 research activity. 
Each sample will include n=1,000 people, 
leading to a total sample size of about n=12,000, 
which will give us a unique resource for 
statistical analyses. The European norm sample 
will include Russia, Germany, France, the United 
Kingdom, Italy, Spain, Poland, The Netherlands, 
Sweden and Denmark, and the inclusion of 
additional countries is still being negotiated. 
To ensure that we obtain high-quality data from 
representative samples, we will subcontract a 
panel research company for data collection, with 
most data obtained via online research panels. 
This exciting project is a fantastic outcome of 
the latest funding round of the EORTC QLG. A 
carefully selected reference population is one 
more important step towards making the new 
EORTC CAT a highly competitive instrument 
among what modern, state-of-the-art quality of 
life assessment currently has to offer.
“We are pleased to announce that this final crucial step of the EORTC 
CAT project has just been launched.”
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Study on European norm data 
for the EORTC CAT is about to start 
 
Sandra Nolte, Department of Psychosomatic Medicine, Center for Internal Medicine 
and Dermatology, Charité - Universitätsmedizin Berlin, Germany
 
WHAT ARE NETs ? 
Neuroendocrine Tumours (NETs) are a group 
of tumours that can arise from most parts 
of the body. The commonest are lung, 
pancreas and gut.
They account for 0.5% of all malignancies 
by incidence (between 3 and 5 per 100,000 
population per year) but with a high prevalence 
of 35 per 100,000 population because of their 
slow tumour growth. This prevalence is greater 
than that of pancreatic and stomach cancer 
combined and incidences have increased 
steadily since the 1970s; this is possibly related 
to better recognition.
Some pancreatic NET tumours (pNET) 
secrete hormones which give characteristic 
systemic symptoms (e.g. hypoglycaemia – low 
blood sugar – from Insulinoma NET), unlike 
those from most cancers which are related to 
the tumour mass effect itself.
WHAT HAS BEEN DONE SO FAR ? 
The EORTC QLQ-GI.NET21 module for patients 
with gastrointestinal neuroendocrine tumours 
was fully validated and published in 2013 on 
behalf of the EORTC Quality of Life Group (QLG) 
(1). Academic requests sent to the EORTC to 
use the GI.NET21 module have been received 
from researchers and clinicians in 83 countries 
and total almost 1,100 requests since 2012. 
Commercial trial contracts to use the module total 
24 from 12 different international companies since 
2008 (EORTC Quality of Life Department (QLD), 
March 2016). 
Patients with pNET were included in the 
GI.NET group but it has become clear that their 
tumours have differences to other GI.NET ones. 
Since there are new drugs being developed 
specifically for pNET there is interest in a 
specific module to be used for pNET patients 
in clinical trials of new compounds.
WHAT ARE WE PLANNING ? 
We already have a lot of GI.NET21 data 
collected from pNET patients over 10 years. 
Some of this is from the GI.NET validation, 
some from global clinical trials which we 
have been involved in, and some from 
online, anonymous data collection from 
pNET patient support groups in various 
countries (coordinated by the UK NET Patient 
Foundation). We can therefore look at the 
performance of the various questions of 
the GI.NET21 in pNET already. However, the 
recently received grant from the QLG, together 
with funding from the NET Patient Foundation, 
will now allow us to develop a specific module 
for pancreatic NET patients. We will use the 
current EORTC QLG guidelines for adapting 
the existing GI.NET21 module and proceed 
from Phases I–III using major NET centres in 
Europe: UK, Berlin, Barcelona, Poland and Milan. 
The study will be managed from Hampshire 
Hospitals NHS Foundation Trust, Basingstoke 
and The University of Winchester, UK.
This is a challenging module to develop, 
since the tumours are heterogeneous, but we 
have accepted the challenge and thank all our 
collaborators, past, present and future.
References 
1. Yadegarfar G, Friend L, Jones, L et al. Validation of the 
EORTC QLQ-GINET21 questionnaire for assessing quality 
of life of patients with gastrointestinal neuroendocrine 
tumours. British Journal of Cancer (2013) 108, 301–310.
 
                                                                      
A project  
to develop a new pancreatic 
Neuroendocrine Tumour 
Module, by adapting the existing QLQ-GI.NET21
Katy O’Donnell & John Ramage, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK 
Liz Friend, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK 
Debra Gray, University of Winchester, Winchester, UK 
Maia Sissons, NET Patient Foundation, UK 
Vassilios Vassiliou, Bank of Cyprus Oncology Centre, Nicosia, Cyprus 
“(...) There is interest in a specific module to be used for pNET patients 
in clinical trials of new compounds.”
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 The EORTC CAT project is completed! 
 
Morten Aa. Petersen & Mogens Grønvold , The Research Unit, Department of Palliative 
Medicine, Bispebjerg Hospital, Copenhagen, Denmark
 
                                                                      
In computerized adaptive testing (CAT) measurement, the questionnaire is adapted to the individual patient, thereby 
optimizing precision, efficiency, and relevance. 
This is achieved by using the responses to the 
previously asked items to select from an item 
bank the most informative next item.
A decade ago the EORTC Quality of Life Group 
(QLG) initiated a project to develop a CAT version 
of the EORTC QLQ-C30. The aim was to develop 
an item bank for each of the fourteen QLQ-
C30 symptom and functional domains. The 
development of these fourteen item banks has 
now been completed!
A total of 230 new items have been developed. 
Together with the QLQ-C30 items, this results 
in a total of 260 items across the item banks, i.e. 
about nine times as many items as in the QLQ-
C30. Each item bank includes between 7 and 
34 items (see Figure 1). Across all the domains, 
the development of all item banks has involved 
researchers and cancer patients from 13 
countries and included more than 300 patient 
interviews and eight data collections comprising 
almost 10,000 patients. 
Preliminary validations of the CAT measures 
based on the data used for the item bank 
developments have indicated average savings 
in sample size requirements of typically 
20–30% compared to using the QLQ-C30 
without reducing the power. Or, equivalently, 
they increase the power by 10–15% without 
increasing the sample size.
A fully functional version of the EORTC CAT 
instrument covering all domains of the QLQ-C30 
is now ready for use. The item banks may also be 
used to form so-called (paper) short-forms. That 
is, items may be selected from the item banks 
and can be added to (selected dimensions 
of ) the QLQ-C30 to improve measurement 
precision. For example, one may wish to add a 
few items to the pain scale to increase precision 
of pain measurement in a study where pain is 
an important outcome. Scores based on such 
short-forms are directly comparable with scores 
based on the EORTC CAT.
The EORTC QLG has decided that, before 
releasing the CAT instrument as a validated 
EORTC tool, the measurement properties need 
to be validated in independent data. Therefore, 
a clinical validation study has been initiated. 
It consists of two parts: a feasibility study 
investigating the acceptability, optimal design 
and logistics of web-based administration of the 
CAT, and a field study testing the “real-life” validity 
and measurement precision of the EORTC CAT. 
At the time of writing the feasibility study has 
just been closed. When the approximately 90 
interviews from cancer patients coming from 
seven countries have been analyzed we will 
initiate the field study, in spring 2016. The field 
study will include 1,000 patients, who will be 
assessed twice: before and after chemotherapy/
radiotherapy.
For more information on the EORTC CAT please 
visit : http://groups.eortc.be/qol/eortc-cat
Fig : Number of items in each 
of the 14 item banks. 
 
LEGEND :  
CF= cognitive functioning 
PF= physical functioning 
EF= emotional functioning 
SF= social functioning 
RF= role functioning 
FA= fatigue 
DY= dyspnea 
NV= nausea/vomiting 
DI= diarrhea 
CO= constipation 
FI= financial impact 
SL= sleep 
AP= appetite loss
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 The EORTC CAT project is completed! 
 
Morten Aa. Petersen & Mogens Grønvold , The Research Unit, Department of Palliative 
Medicine, Bispebjerg Hospital, Copenhagen, Denmark
 
CHES.EORTC 
platform: 
development of 
an online platform to support module development 
and dissemination of the EORTC CAT measures
The current CHES.EORTC version, accessible online via the EORTC Quality of Life Group (QLG) website, 
provides essential features for quality of life 
(QoL) data collection in routine cancer care 
including graphical presentation of the results 
of individual patients. This system is currently 
supplemented with further software features 
to support EORTC instrument development 
as well as the dissemination and the use of 
the EORTC CAT measures.
CHES.EORTC FOR INSTRUMENT DEVELOPMENT
The supplemented version will help 
to enhance scientific standards of the 
development of EORTC QoL measures 
(including modules and CAT) and facilitate 
data collection in EORTC QLG module and CAT 
development studies. It will allow electronic 
questionnaire administration, completion 
of electronic case report forms and data 
storage on a central server. The system 
will support the strategy of the Module 
Development Committee to extend the Data 
Repository Project in a way that facilitates and 
harmonizes further module development. 
 The new platform will build on the 
existing CHES.EORTC version and specific 
implementations that have been used for data 
collection within two module development 
Phase IV studies (QLQ-TC26 and QLQ-BRR24). 
In addition, it will help to standardize the 
collection of medical and sociodemographic 
data by use of templates for case report forms.
CHES.EORTC FOR  CAT DEVELOPMENT AND
DISSEMINATION
The ongoing EORTC CAT validation studies 
(see p.14) are using CHES.EORTC for CAT 
administration and electronic capture of 
medical and sociodemographic data. For this 
purpose an interface has been programmed 
to link the so-called CAT engine containing the 
CAT algorithm and settings with CHES.EORTC.
CHES.EORTC adds an elaborated graphical 
user interface for item display on a wide 
range of electronic devices, for data storage, 
management of study participants (including 
user accounts for patients allowing assessments 
outside the hospital), electronic case report 
forms, and other features outlined above.
Although these features are sufficient 
to meet the requirements of the EORTC 
CAT validation project, further software 
development will probably be needed to allow 
unrestricted dissemination of the EORTC CAT 
measures within the QLG.
BENEFITS OF THE NEW CHES.EORTC PLATFORM
We think that CHES.EORTC is essential for the 
use of the EORTC CAT measures by allowing 
CAT administration without any local software 
installation. Being able to rely on CAT software 
provided by the EORTC QLG minimizes costs 
that are introduced by having to buy and 
implement an appropriate software package for 
individual studies or centres. 
The CHES.EORTC platform outlined above will 
support the development and dissemination 
of the EORTC QoL measures. It will facilitate 
module development studies, enhance 
harmonization of research protocols and 
support and complement the Data Repository 
Project. In addition CHES.EORTC will enable the 
dissemination of the newly developed EORTC 
CAT measures within the QLG.
Please visit us on the EORTC QLG website 
(http://groups.eortc.be/qol/electronic-version-
cheseortc), try our newly developed features, 
and do not hesitate to provide suggestions or 
comments! Email : bernhard.holzner@ches.pro
 
Bernhard Holzner, University of Innsbruck, Austria 
Johannes M. Giesinger, Netherlands Cancer Institute, Amsterdam, The Netherlands 
Gerhard Rumpold, Evaluation Software Development, Rum, Austria
                                                                      
Fig : Start screen of the CHES.EORTC platform (left) and demonstration of the computer-adaptive EORTC fatigue measure (right)
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MULTI-ATTRIBUTE UTILITY IN CANCER (MAUCa) CONSORTIUM MEMBERS: 
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Neil Aaronson: Amsterdam, The Netherlands  |  John Brazier, Donna Rowen, Tracey Young: Sheffield, UK  | 
David Cella; Simon Pickard: Chicago, USA  | Peter Fayers: Aberdeen, UK & Trondheim, Norway | Monika Janda: Brisbane, Australia | 
Georg Kemmler: Innsbruck, Austria | Julie Pallant: Melbourne, Australia | 
Stuart Peacock;  Helen McTaggart-Cowan: Vancouver, Canada | Galina Velikova: Leeds, UK | 
 
The QLU-C10D:
a utility measure derived from the QLQ-C30 
 
Madeleine King, MAUCa Consortium Chair, University of Sydney, Australia
 
                                                                      
Ihave had the privilege of working with an outstanding international team including several members of the EORTC 
Quality of Life Group (QLG) over the last six 
years to develop the QLU-C10D as a means 
to include quality of life (QoL), as assessed 
by the QLQ-C30, into economic evaluation of 
cancer therapies. This remarkable brains-trust 
– collectively called the MAUCa Consortium – 
included health economists, oncologists, 
behavioural scientists, statisticians and 
psychometricians. I am greatly indebted to their 
commitment and contribution to our shared 
goal over these many years.
WHY WAS THE QLU-C10D NEEDED ? 
The EORTC’s QLQ-C30 is the heart of 
the EORTC’s modular approach to QoL 
assessment, and is the most commonly used 
QoL questionnaire in cancer clinical trials 
internationally. Its scoring algorithm produces 
15 scales, providing a comprehensive profile 
of patient-reported outcomes (PROs) that are 
important to patients and their health care 
providers. However, as originally designed, the 
QLQ-C30 cannot be used in health economic 
analysis because it is not a preference-based 
measure (or utility measure). 
Utility measures integrate people’s 
preferences for different aspects of quality of 
life and survival, and the trade-offs that often 
arise with cancer treatments, into a single 
number: a utility score. Utility has a maximum 
of 1 (full health), is anchored at 0 (death) and 
can have negative values (health states worse 
than death). This can be used in economic 
evaluations to weight survival by QoL, yielding 
quality-adjusted life years (QALYs).
Common utility measures include the EQ-5D, 
HUI3 and SF-6D. Although these measures are 
widely used, they are generic, and therefore 
may not be particularly sensitive when used in 
cancer populations. Further, the use of several 
questionnaires (e.g. QLQ-C30 for QoL endpoints 
and EQ-5D for health economics) adds to PRO 
completion time and patient burden.
THE NEWEST MEMBER OF THE EORTC 
QoL FAMILY
The QLU-C10D was endorsed by the EORTC 
QLG Executive Committee (EC) in April 2014, 
and in September 2015 the EC agreed that the 
EORTC QLG would be responsible for all aspects 
of the ongoing management of the QLU-
C10D, including developing and maintaining 
information about administration, scoring and 
interpretation, housing relevant materials on the 
EORTC QLG website, maintaining control of the 
standard versions, and granting permission for use. 
The EORTC QLG Health Technology 
Assessment (HTA) working group, led by Georg 
Kemmler and Eva Gamper, will take on the 
important task of developing a user manual and 
reference values, as well as the other important 
and interesting research they described in the 
QLG’s spring 2015 Newsletter.
WHY IS IT CALLED “QLU-C10D” ? 
As Georg and Eva explained in their 
newsletter article last year, this name was 
decided in consultation with the EORTC QLG EC: 
• “QLU” indicates it is a utility measure; 
• “C” indicates its origin in the EORTC’s 
core questionnaire;
• “10D” indicates 10 domains (mobility, role 
functioning, social functioning, emotional 
functioning, pain, fatigue, sleep, appetite, 
nausea, bowel problems). 
IS THE “QLU-C10D” READY TO USE ? 
So far, work has focussed on development of 
the QLU-C10D, including the descriptive system 
(or “health state classification system”) and a 
robust method for developing utility weights (1,2). 
That valuation method is now being rolled out, 
using standardized methodology, in a number of 
countries to develop a range of country-specific 
utility scoring algorithms and utility value sets. 
Georg and Eva are leading valuations in five 
European countries. I am leading the Australian 
valuation, funded by the NHMRC grant noted 
below – this work is almost complete, and a 
paper is in preparation. I am currently preparing to 
undertake valuations for UK and USA, funded by 
AbbVie through Evidera – this work will take about 
a year to complete.
While the QLU-C10D is not quite ready for 
prime time yet, it can be included in clinical trials 
in development now, safe in the knowledge that 
scoring algorithms are in the pipeline. As soon as 
each QLU-C10D utility scoring algorithm has been 
finalized and published, it can be used to derive 
utility scores from QLQ-C30 data, which can then 
be incorporated into health economic modelling .
For full details of the first two steps in the 
development of the QLU-C10D:
1. King MT, Costa DSJ, Aaronson NK, Brazier 
JE, Cella D, Fayers PM, Kemmler G, Norman 
R, Pickard AS, Rowen D, Velikova G, Young 
TA, Viney R, on behalf of MAUCa Consortium. 
QLU-C10D: a health state classification system 
for a multi-attribute utility measure based 
on the EORTC QLQ-C30 Quality of Life Research. (2016); 
25 (3):625–636. DOI 10.1007/s11136-015-1217-y 
2. Norman R, Viney R, Aaronson N, Brazier JE, 
Cella D, Costa DSJ, Fayers P, Kemmler G, Peacock S, 
Pickard AS, Rowan D, Street DJ, Velikova G, Young 
T, King MT on behalf of MAUCa Consortium. Using a 
discrete choice experiment to value the QLU-C10D: 
feasibility and sensitivity to presentation format. 
Quality of Life Research (2016) 25:637–649 DOI 10.1007/
s11136-015-1115-3
Funding for the work described in these publications: 
Australian National Health and Medical Research Coun-
cil (NHMRC) Project Grant 632662
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Symptom-based questionnaires in the QLG
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2  The Academic Medical Center (MAGS), Amsterdam, the Netherlands 
3  GIMEMA Data Center, Rome, Italy 
4  Swansea University, Swansea, UK 
5  Head of Quality of Life Department, EORTC Headquarters, Brussels, Belgium   
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The last 10 years have seen huge interest in Patient-Reported Outcome Measures (PROM) stimulated by 
the requirement to use them to acquire 
data for product registration applications 
in Europe and North America. However, it 
has become clear that the FDA in America, 
in particular, is concerned primarily with 
PROMs of symptoms, rather than quality of 
life (QoL), which encompasses functional 
and psychological components as well as 
symptoms of the disease and toxicities of 
the treatment.
The EORTC Quality of Life Group (QLG) is a 
leading developer of PROMs, with an item 
bank containing over 600 validated questions 
relating to all aspects of health-related QoL. 
Many of these ask about symptoms and 
toxicities. The QLG has set high standards for 
the development of QoL questionnaires, with 
detailed guidelines for questionnaire (module) 
development. These work well for creating 
new modules to cover QoL aspects of living 
with, and receiving treatment for, a particular 
cancer. What is increasingly required, however, 
is a means to assess the effects of a newly 
developed treatment, so that PRO data for 
registration can be acquired efficiently.
We set out to answer the following questions:
• Can we use or adapt existing items from the 
EORTC QLG Item Bank to create a symptom-
based questionnaire (SBQ)?
• Can we use or adapt existing QLG methods to 
develop an SBQ?
• What are the essential steps in doing 
the above?
The SBQ project set out to create symptom 
checklists related to biological treatments 
(targeted therapies) in three tumour types. 
We chose breast cancer (common tumour, 
with an existing module), chronic myeloid 
leukaemia (CML; haematological, with a 
module in development), and gastrointestinal 
stromal tumour (GIST; rare, no existing 
module). We have recorded the time spent 
on each step of the procedure, using the full 
EORTC QLG Guidelines, and we will assess the 
contribution made at each step, so we can 
determine the most time-efficient means of 
SBQ development.
We have published two systematic reviews 
of symptoms reported by patients receiving 
targeted therapies (1, 2). Preliminary analysis 
of Phase I interviews with patients and 
professionals suggests that patients report 
additional symptoms to those identified by 
literature review. Phase I data indicated that 
similar symptoms were reported by patients 
with different tumour types who were 
receiving similar targeted therapies. This led us 
to develop a single SBQ for targeted therapies 
for testing in Phase III in breast, CML and GIST 
patients. Data collection for Phase III will be 
finished in spring 2016.
When Phase III data are fully analyzed we 
anticipate the QLG will conduct an open 
debate on how to meet the challenge of 
regulatory requirements for PROMs and PROM 
development. Should we focus only on QoL? 
Or should we use our expertise and our large 
item bank of validated questions to construct 
SBQs to document and grade symptoms 
and toxicities if this is required by academic 
researchers or pharma? If we consider providing 
SBQs, what minimum justification should be 
applied for inclusion of items, and how do we 
construct new items if these are required?
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INTRODUCTION
Fatigue is one of the most distressing 
symptoms for cancer patients, affecting their 
quality of life in all phases of the treatment 
or stages of the disease. During the last 
decade, interest and research output in 
cancer-related fatigue (CrF) has increased 
considerably and, therefore, more detailed 
uni- or multi-dimensional instruments have 
been developed to assess CrF (1, 2). The Phase 
III module EORTC QLQ-FA13 (3) is based on a 
multidimensional concept of fatigue including 
physical, emotional and cognitive domains. 
The module may be used in all treatment 
options (chemotherapy, radiation, surgery, 
targeted therapies) and all settings of health 
care (acute care, rehabilitation, hospice care). 
As a symptom-targeted module, QLQ-FA13 
measures fatigue in all tumour diagnoses as 
well as in all phases and stages of cancer. 
DESIGN AND METHODS
The psychometric validation includes 
the evaluation of the scale structure of the 
QLQ-FA13 using confirmatory analyses, 
the analysis of test-retest reliability and 
internal consistency, and the analysis of the 
responsiveness to change. The design for the 
psychometric evaluation of the QLQ-FA13 
followed the EORTC Quality of Life Group 
(QLG)’s module development guidelines (4). 
Patients were enrolled in four parallel groups 
addressing patients under treatment treated 
with curative intention (group A) and palliative 
intention (group B) as well patients off 
treatment (group C) and long-term survivors 
(group D). 
The study was carried out in an international 
multi-centre fashion from February 2011 to 
November 2014 at 17 centres in 11 European 
and non-European countries (Europe: 
England, France, Germany, Austria, Poland, The 
Netherlands, Sweden, Spain, Italy; non-Europe: 
Egypt and Taiwan). For Phase IV the QLQ-FA13 
was translated into the languages of the 
cooperating countries according to the EORTC 
QLG’s Translation Procedure (5). 
The module includes 13 items (11 items 
in three subdimensions – “physical fatigue”, 
“emotional fatigue” and “cognitive fatigue”; 
and 2 global items (item FA12: “Did tiredness 
interfere with your daily activities” and item 
FA13: “Did you feel that your tiredness is not 
understood by the people who are close 
to you?”)). We used a confirmatory factor 
analysis to validate the a priori defined three-
dimensional structure of the QLQ-FA13 in 
conjunction with the two global items as 
criteria. 
The total sample of patients recruited in 
all groups was n=946. The average age was 
58.7 (sd 13.1 years) (range from 22–97 years). 
Patients were recruited in Germany (16.1%) 
and Poland (15.6%), followed by UK (11.1%), 
Sweden (10.0%), Egypt (9.9%), Spain (8.4%), 
The Netherlands (7.2%), Italy (5.0%), Austria 
(4.5%) and Taiwan (3.8%). Gender distribution 
was balanced (female 54.1%, male 45.9%). 
As planned, the sample comprised a wide 
spectrum of tumour diagnoses with the 
highest percentages in breast cancer (24.0%), 
head and neck cancer (22.6%), lung cancer 
(11.1%) and colorectal cancer (9.5%).
RESULTS
As a result of our study, we present a 
slightly revised Phase IV module, the EORTC 
QLQ-FA12. The international cross-cultural 
validation of this module, including a large 
and representative sample of cancer patients, 
enables generalization of the results and 
guarantees the cross-cultural applicability of 
this module. The results of the confirmatory 
factor analysis show that the Phase III 
QLQ-FA13 did not reach a sufficient model fit 
for all items and therefore had to be modified. 
The changes include the elimination of a single 
item (FA11) and the allocation of one item 
(FA05) to the physical dimension instead of the 
cognitive dimension. The inter-correlation of 
FA11 within the factorial structure showed that 
this item may be not sufficiently understood 
as part of the cognitive dimension; in addition, 
it did not allow a clear allocation to the three 
dimensions and showed low factor loading in 
all three factors ≤.35. As there is only a minor 
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loss of information we decided to eliminate 
this item. In contrast, the allocation of item 
FA05 to the physical dimension improved the 
model fit substantially. In total, by these slight 
changes the model was able to be improved 
and we attained very good scores for the 
model fit (see Figure 1). A cross-validation of 
the data confirmed the results of the changed 
model. In terms of convergent and divergent 
validity, all coefficients for the model fit 
showed very good to excellent fit. In addition, 
acceptable to very good scores for the 
internal reliability (Cronbachs α from .79 to .90) 
were found.
Analysis of test-retest reliability was 
conducted in two groups of patients, both off 
treatment. The results show a high correlation 
for all fatigue scores between t1 and t2 with 
an average time difference of nine days which 
indicates a stable measurement of fatigue by 
the QLQ-FA12 over a time where no changes 
of fatigue are expected. The analyses of 
the sensitivity to change detected different 
results for the patients in curative treatment 
compared with patients under palliative 
treatment.  
CONCLUSION
In conclusion, the QLQ-FA12 is now 
available as an internationally fully validated 
Phase IV module to be used for measuring 
cancer-related fatigue in clinical trials in 
conjunction with the QLQ-C30. The QLQ-FA12 
may be also used to assess fatigue symptoms 
in clinical practice or quality assurance to 
assess care needs. The module is currently 
available in the following languages: English, 
Dutch, German, Polish, Italian, French, Spanish, 
Swedish, Norwegian, Arabic and Mandarin, 
and is soon to be available via the EORTC QLG 
website. 
 
The international 
psychometric validation (Phase IV) 
of the EORTC fatigue module (EORTC QLQ-FA12) 
 
Joachim Weis, University Clinic Centre Freiburg, Germany 
 
On behalf of the co-investigators : Krzysztof Tomaszewski, Eva Hammerlid, Juan Ignacio Arraras, Thierry Conroy, 
Anne Lanceley, Heike Schmidt, Susanne Singer, Monica Pinto, Mohamed Alm El-Din, Inge Compter, 
Bernhard Holzner, Dirk Hofmeister, Wei-Chu Chie, Marek Czeladzki, Amelie Harle, Louise Jones, Sabrina Ritter, 
Markus Wirtz, Henning Flechtner, Andrew Bottomley
References 
1. Bower JE, Bak K, Berger A, Breitbart W,  Escalante CP, 
Ganz PA,Schnipper HH, Lacchetti C, Ligibel JA,  Lyman 
GH,  Ogaily MS,  Pirl WF,  Jacobsen PB. (2014) Screening, 
Assessment, and Management of Fatigue in Adult 
Survivors of Cancer: An American Society of Clinical 
Oncology Clinical Practice Guideline Adaptation. JCO, 32, 
DOI: 10.1200/JCO.2013.53.4495 
2. Minton O, Stone P. (2009) A systematic review of the 
scales used for the measurement of cancer-related fatigue 
(CRF). Annals of Oncology; 20:17–25.
3. Weis J, Arraras JI, Conroy T, et al. (2013) Development 
of an EORTC quality of life phase III module measuring can-
cer-related fatigue (EORTC QLQ-FA13). Psychooncology. 
22:1002–7.
4. Johnson CD, Aaronson A, Blazeby JM, Bottomley 
A, Fayers P, Koller M, Kuliś D, Ramage J, Sprangers M, 
Velikova G, Young, T (2011) Guidelines for Developing 
Questionnaire Modules (4th Edition). Brussels: EORTC 
Quality of Life Group Publication. ISBN 978-2-930064-413.
5. Dewolf L, Koller M, Velikova G, Johnson C, Scott 
N, Bottomley A. (2009) EORTC Quality of Life Group 
Translation Procedures (3rd Edition). Brussels: EORTC 
Quality of Life Publication. EORTC Publication . ISBN 
978-2-930064-38-3.
Fig. 1: Graphical presentation of the confirmatory analysis (revised model):  Legend:  FA12/FA13 = criteria variables; physical fatigue, 
emotional fatigue, cognitive fatigue = latent constructs; FA1–FA13 = single items of the questionnaires; e1 to e13 = error variables.
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Manchester Town Hall (left) 
Manchester United’s Old Trafford: 
The “Theatre of Dreams” (right)
I would like to extend a warm invite to you all to Manchester, England for the 2016 EORTC Quality of Life Group (QLG) 
autumn meeting. The meeting will be held 
on the 22nd and 23rd September 2016 in the 
Manchester Town Hall. 
Located in the north-west of England, the city 
of Manchester is surrounded by the Cheshire 
Plain, the Pennines and an arc of towns. A boom 
in textile manufacturing during the Industrial 
Revolution led to Manchester becoming 
the world’s first industrialized city and it was 
awarded city status in 1853.
With a rich history and culture, Manchester 
is notable for many things including world-
famous music acts and sports teams along with 
its architecture, culture, nightlife and scientific/
engineering outputs. The Town Hall is located 
in the city centre and is an iconic landmark in 
Manchester (in fact it is in TripAdvisor’s top 10 
things to see in Manchester!). Built in 1877, 
the building is regarded as one of the finest 
examples of Neo-Gothic architecture in the UK 
and one of the most important Grade I listed 
buildings in England. Our meeting will take 
place in a variety of grand ceremonial rooms 
within its walls. More information can be found 
at: www.manchester.gov.uk/townhall
Our Thursday night dinner and disco will be in 
a somewhat different setting: in stark contrast 
to the Town Hall, we will be dining at Old 
Trafford, the world-famous stadium and home 
of Manchester United Football Club. Now, I 
realize you might not all share our nation’s love 
of football but I think you will agree that the 
panoramic view of the pitch from the glass-
fronted Trafford Suite with a glass of bubbly 
in hand is still an exciting opportunity for a 
selfie! For those wishing to explore the “Theatre 
of Dreams” further, the stadium also offers 
daily tours and a museum with a vast array of 
trophies. Please see www.manutd.com/en/Visit-
Old-Trafford.aspx for further details.
A relaxed dinner on the Friday night will be 
held just across the square from the Town Hall. 
The Albert Square Chophouse is housed within 
the Memorial Hall, an iconic listed building 
dating from 1866 which was once a Victorian 
warehouse. The food will be “classic British 
cooking with a modern twist”.
For your spare time there are plenty of other 
places to visit in and around Manchester 
(www.visitmanchester.com). A key part of 
Manchester’s culture revolves around music: 
the city has a large number of performance 
venues including the renowned Manchester 
Opera House, the Palace Theatre and the largest 
concert arena of its type in Europe. There are 
also many smaller theatres, music venues 
and a thriving nightlife scene – the variety 
of entertainment on offer promises to have 
something to suit every taste. In addition, the 
shopping area is large and diverse, ranging from 
quirky independent shops to large designer 
brands and all within walking distance of each 
other in the city centre. For those extending 
their stay, the surrounding Cheshire countryside 
is also worth a visit with plenty of walking 
routes and historic houses to explore. By train 
you can also visit the Lake District National Park 
or explore the Pennine Way.
Manchester is easily accessible by train, air or 
road. The airport is only 20 minutes by train 
from the city centre (www.manchesterairport.
co.uk/to-and-from-the-airport). There are 
many hotels to choose from to suit all budgets 
(recommendations will be provided via email 
to attendees).
I look forward to welcoming you all to 
Manchester !
EORTC QoL Group 
autumn 2016 
meeting in England 
 
Kim Cocks, Adelphi Values, Cheshire, UK
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Manchester Town Hall (left) 
Manchester United’s Old Trafford: 
The “Theatre of Dreams” (right)
T he EORTC Quality of Life Group (QLG)’s autumn meeting of 2015, hosted by Dr Iwona Tomaszewska 
and Dr Krzysztof Tomaszewski of the 
Jagiellonian University Medical College, 
was held in the culturally rich city of 
Krakow, Poland. Krakow’s historic city 
centre is listed on UNESCO’s World 
Heritage Site and was the cultural capital 
of Europe in the year 2000. Not only is the 
city rich with culture, with its many churches 
and museums, it is also a major centre of 
education with a population of over 200,000 
students. Krakow has 24 institutions of higher 
education, including Poland’s oldest university, 
Jagiellonian University. 
The meeting took place in the Grand Hotel. 
Originally a palace from 1887, it is now a 5-star 
hotel right in the heart of the city, just 100m 
from the Main Market Square (Rynek Główny). 
Rynek Główny is one of the oldest and biggest 
market squares in Europe. It has numerous 
wonderful cafés, bars and restaurants, and the 
renaissance Cloth Hall (Sukiennice) right in the 
middle of the square. At the edge of the market 
square is St. Mary’s Basilica (Kościół Mariacki) 
with its famous trumpet player. Every hour the 
trumpeter plays a tune from the highest tower 
of St. Mary’s Basilica and then suddenly stops. 
The tune, called “Hejnal”, was the signal to 
open or close the gates. Legend has it that in 
the Middle Ages a tower guard saw the Tatars 
coming from the northern tower of the church 
and wanted to warn his fellow citizens, so he 
played his trumpet. Unfortunately, his trumpet-
playing was suddenly cut short because he was 
hit by an arrow. However, the city gates were 
closed just in time and the Tatar attack was 
averted. Since the 19th century, the Hejnal is 
played in commemoration of this event. Fun 
fact: since 1927, Polish Radio has played this 
melody every day at 12 noon.
Since this was the first time that I attended an 
EORTC QLG meeting, and especially since I was 
there to present my own research project for 
the first time, I was excited and nervous to see 
what these meetings entailed. The QLG chair, 
Lonneke van de Poll, opened the meeting 
with a warm welcome and introduction. After 
a word from the Head of the EORTC Quality 
of Life Department (QLD), Andrew Bottomley, 
the parallel sessions started. What I quickly 
discovered during the sessions is that the 
members of the QLG are very invested in each 
other’s work. I was impressed by the relaxed 
and informal but sincerely passionate way 
they debated the discussion points presented 
to them and their willingness to assist in and 
contribute their expertise to one another’s 
research projects.  
The parallel sessions were mainly held on 
Thursday 10th September. There were many 
sessions dedicated to the latest progress of the 
numerous questionnaires and modules being 
developed. I also had the privilege of present-
ing my research project, the development 
of an I-ADL questionnaire for brain tumour 
patients. Furthermore, I attended sessions on 
the Cancer Survivorship Questionnaire and 
the Computer Adaptive Testing Project (CAT), 
where recent developments and progress 
were reported. We were also introduced to 
a new aspect of the QLG: the Clinical Project 
Development Committee (CDC).
In addition to the inspiring sessions during the day, 
there was plenty of time for sightseeing and fine 
dining. After Thursday’s sessions, we all boarded 
electric power cars (we called them tuk-tuks) for 
a tour around Krakow’s Old Town and the Wawel 
Castle, where we learned the legend of the dragon 
(Smok Wawelski). In the evening we dined at the 
oldest and most famous restaurant in Krakow, 
the Wierzynek.
On Friday 11th September, there was the Module 
Development Committee (MDC) and CDC session 
and business meeting in the morning. In the 
afternoon plenary session, Madeleine King and 
Georg Kemmler presented their Australia–Austria 
collaborative project on Health Technology 
Assessment (HTA) and Susanne Singer updated 
us on the H&N35 module. By then, the sunlight 
was so bright that the glass roof of the hotel’s 
conference room needed to be covered in order 
to allow us to continue to read to the slides on 
the screen. The meeting was concluded with the 
introduction of the 2016 spring meeting in Oslo. 
Later that evening, the second sightseeing tour 
commenced. We were shown the impressive 
and slightly chilling history of the Old Jewish 
Quarters (Kazimierz) and Oscar Schindler’s Factory. 
Afterwards, we dined at a typical Polish restaurant 
on many Polish specialities – and of course some 
raspberry and lime vodka.
All in all, it was a spectacular meeting with an 
abundance of knowledge being shared in a lively 
and inspiring way, in a beautiful city with delicious 
food and with a great group of people. I am 
already looking forward to the spring meeting in 
Oslo. Many thanks to Drs Iwona Tomaszewska and 
Krzysztof Tomaszewski for organizing this event!
Image courtesy of www.manchester.gov.uk
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